Corporate Symposia

Corporate Symposia

*Lunch boxes will be provided to the session attendees (marked with* below)

Corporate Symposium (CS01) | Servier*

New Developments in Glioma Care: A Focus on Mutant IDH Inhibition

Click on the Opens external link in new windowlink to register.

Friday, September 22, 13:15 - 14:15 hrs, Grote Zaal

13:15 – 13:20

Welcome & Introduction

Meeting objectives; speaker introduction; agenda; housekeeping

Carmen Balaña , Spain

Unmet needs in current glioma management

Riccardo Soffietti, Italy

13:20 – 13:35

From Concept to Clinic – understanding the Journey to INDIGO.

Rapid overview of the development of IDH mutation inhibitors for glioma.

Tim Cloughesy, United States

13:35 – 13:50

Interpreting pivotal clinical data in IDH Mutated Glioma in light of prior research and current practice.

A deep dive into the results of the INDIGO trial in the context of previous studies and current clinical management

Martin van den Bent, Netherlands

13:50 – 14:00

Beyond the numbers: Contextualizing evidence through a patient case study

Review of a patient case to illustrate the experience with IDH mutation inhibitors

Mehdi Touat, France

Envisioning the future of glioma management with molecular targeted therapy

How will IDH mutation inhibitors change the future of the clinical management of glioma?  Which patient population are likely to benefit from the treatment?

Matthias Preusser, Austria

13:30 – 13:45

 Q&A and Panel Discussion

All Faculty members, moderated by: Carmen Balaña , Spain


Corporate Symposium (CS02) | SERB Pharmaceuticals*


Friday, September 22, 13:15 - 14:15 hrs, Van Weelde Zaal

13:15 – 13:30

HDTMX: a Cornerstone in Neuro-Oncology

Scott Howard, United States

13:30 – 13:45

Maximising Patient Care: Examples from the EU Registry

Madhumita Dandapani, United Kingdom

13:45 – 14:00

 Strategies to Improve HDMTX Outcomes: Updates from the METHOGLU Study

Caroline Houillier, France
14:00 – 14:15Summary, Practical Advice, and Audience

All speakers


Corporate Symposium (CS03) | Chimerix

H3 K27M-mutant Diffuse Glioma: Diagnosis to Treatment and Future Directions

Saturday, September 23, 13:00 - 14:00 hrs, Grote Zaal

13:00 – 13:05


Allen Melemed, United States

13:05 – 13:20

Epidemiology and Diagnosis of H3 K27M Diffuse Glioma

Pieter Wesseling, Netherlands

13:20 – 13:35

Treatment Landscape

Susan Short, United Kingdom

13:35 – 13:50

ACTION: Phase 3 Trial of ONC201 in H3 K27M-mutant Diffuse Glioma

Martin van den Bent, Netherlands

13:50 – 14:00

Panel Discussion and Q&A



Corporate Symposium (CS04) | Novocure*

Tumor Treating Fields: In Application

Saturday, September 23, 13:00- 14:00 hrs, Willem Burger Zaal

Chairs: Martin Glas, Roberta Rudà

13:00 – 13:05


Martin Glas, Germany

13:05 – 13:15

TTFields therapy concomitant with TMZ and Lomustine

Martin Glas, Germany

13:15 – 13:25

Real-world experience with TTFields in GBM

Martin Misch, Germany

13:25 – 13:35

Investigating TTFields with ICI in GBM

Michael Weller, Switzerland
13:35 – 13:55Q&A Session
Elizabeth Moyal, France; Martin Glas, Germany